Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 21,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Lymphoma, Non-Hodgkin
Interventions: Recombinant Human Interleukin-2 and Rituximab; Drug
Lead sponsor: Chiron Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Tucson, Arizona • Newport Beach, California • Sacramento, California + 28 more

Conditions: Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Interventions: Mobile Cardiac Telemetry, Wearable Cardiac Monitor; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: HIV/AIDS, Nicotine Dependence
Interventions: Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention; Drug · Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab; Biological
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: HIV LFn-p24; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Type 1 Diabetes
Interventions: Insulet Artificial Pancreas (AP) System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Palo Alto, California • Santa Barbara, California • Walnut Creek, California + 1 more

Conditions: Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions: NeoMatriX Wound MatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: AID System, Insulin Lispro; Device · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: Tucson, Arizona • Orland Park, Illinois • Ann Arbor, Michigan + 8 more

Conditions: Asthma
Interventions: Apieron Insight eNO monitor; Device
Lead sponsor: Apieron; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Mission Viejo, California • San Jose, California • Glastonbury, Connecticut + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Indocyanine green, MultiSpectral Imaging System; Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: Sleep Innovations for Preschoolers with Arthritis (SIPA); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 2 Years to 5 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, UMEC, VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Newport Beach, California • San Diego, California • Upland, California + 11 more

Conditions: Lymphoma
Interventions: TAK228, Blood Sugar Testing; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV/AIDS
Interventions: DuoPACT, Life Steps; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breathing, Mouth, Lung Function Decreased, Vocal Cord Dysfunction, Laryngeal Obstruction, Asthma
Interventions: Impulse Oscillometer; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions: durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type I Diabetes
Interventions: Placebo GABA and Placebo GAD-alum, GABA and Placebo GAD-alum, Active Oral GABA and Active GAD-alum injection; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 4 Years to 18 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sjogren's Disease
Interventions: Administration of Lotemax; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections, Peripheral Nervous System Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more

Search by objective public record fields.

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Optimizing Tobacco Use Treatment for PLWHA

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

Insulet Artificial Pancreas Early Feasibility Study

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Phase II Study of TAK228 in Relapsed Lymphoma

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

DuoPACT Pilot Intervention

Evaluating the Use of a Device Called Impulse Oscillometry in Participants With Vocal Cord Disorders or Asthma

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs